During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, ú8 mg/mL). A macrolide (seven received clarithromycin, one azithromycin) and clofazimine were continued; additional treatment included various combinations of ethambutol, ciprofloxacin, amikacin, and rifabutin. After the detection of a resistant isolate and before receipt of additional antimycobacterials, the median peak MAC colony count in blood was 105 cfu/mL (range, 8 -81,500 cfu/mL). After additional antimycobacterials, the median nadir MAC colony count was 5 cfu/mL (range, 0 -110 cfu/mL). Five (63%) of eight patients had a §1 log 10 decrease, including two who achieved negative blood cultures; all of these responses occurred in patients originally assigned to clarithromycin plus clofazimine. Treatment of clarithromycin-resistant MAC bacteremia that emerges during clarithromycin-based treatment can decrease levels of bacteremia and transiently sterilize blood cultures.
Recent randomized studies have investigated clarithromycin-
An initial bacteriologic response occurred in 69% of both treatment groups. Clarithromycin resistance occurred at a median based combination regimens for initial treatment of Mycobacterium avium complex (MAC) bacteremia in AIDS [1 -4] . In of 16 weeks in subjects receiving two drugs and of 40 weeks in those receiving three drugs (P Å .004) [3] . This report studies in which ethambutol was included in the initial regimen for all clarithromycin-treated patients, the detection of clarsummarizes the response to additional antimycobacterial therapy in the eight subjects in that trial who had recrudescent ithromycin-resistant MAC has been uncommon [1, 2] . The incidence, course, and treatment of disease caused by clarithrobacteremia with clarithromycin-resistant MAC. mycin-resistant MAC that emerges during clarithromycinbased combination therapy have not been described. any patients with clarithromycin-resistant MAC bacteremia than in the six receiving clarithromycin/clofazimine (12 -16 that developed during prophylaxis, our results suggest that weeks), similar to the results for the study as a whole [3] . treatment of such patients is likely to be at least partially Seven of the eight patients who received additional antimysuccessful. cobacterials had achieved negative blood cultures before isolaThe role of continuing macrolide therapy in patients who tion of resistant MAC. A macrolide (clarithromycin in seven, have developed clarithromycin-resistant MAC bacteremia is azithromycin in one) was continued in all patients. Amended unclear, but all of our patients continued to receive a macrolide. regimens included various combinations of ethambutol, ciLending support for this practice is the finding that at the time profloxacin, amikacin, and rifabutin (table 1). After the detecof autopsy of patients who died while receiving clarithromycintion of a resistant isolate and before the introduction of addibased treatment regimens for MAC bacteremia, both clarithrotional antimycobacterial drugs, the median peak colony count mycin-susceptible and clarithromycin-resistant MAC are in blood was 105 cfu/mL (range, 8 -81,500 cfu/mL). Bacterpresent in tissues [9] . Although our practice is to continue emia decreased at least transiently in all eight subjects. After macrolides if they are being well-tolerated, a randomized trial additional antimycobacterials, the median nadir colony count will be required to examine the value of this strategy. was 5 cfu/mL (range, 0 -110 cfu/mL). Five (63%) of eight had
Methods
The best microbiological responses occurred in the subjects a §1 log 10 decrease; all of these responses occurred in patients whose initial therapy for bacteremia did not include ethambuoriginally assigned to the clarithromycin/clofazimine arm. Two tol. Five of these six had ethambutol added after the emergence of these five responders (two of eight overall, 25%) again of clarithromycin resistance. Thus, ethambutol may have been achieved negative blood cultures, but both eventually relapsed essential to the improved response. Ethambutol had modest (patients 1 and 4). Three (37%) of eight did not have a §1 activity as monotherapy against MAC [10]; it reduced bacteriolog 10 decrease in MAC colony count. The two subjects whose logic relapse and delayed the development of clarithromycin initial therapy consisted of clarithromycin/clofazimine/ethamresistance in AIDS patients with MAC [3]. The two patients butol (patients 7 and 8) and one who initially received clarithrowhose initial treatment included ethambutol had a poorer remycin/clofazimine (patient 3) had only transient responses to sponse to additional antimycobacterial drugs. In both, only a additional antimycobacterials.
single agent was added to their regimens. Most patients with MAC bacteremia will have already been treated with ethambuDiscussion tol [1 -4] were not achieved, although one patient had clearance of bac-
